Cagrilintide vs CagriSema — which one to pick

When Novo Nordisk’s cagrilintide hit Phase 3 monotherapy trials in 2024-2025, people started asking the obvious question: if cagrilintide is the cagri in CagriSema, why pair it with semaglutide at all?

The answer comes down to mechanism, magnitude, and side-effect profile.

What they are

• Cagrilintide is a long-acting amylin analog. Once-weekly injection. Slows gastric emptying, suppresses post-meal glucagon, reduces appetite via the area postrema in the hindbrain.
• CagriSema is cagrilintide + semaglutide in a single injection. Adds GLP-1 receptor agonism on top of amylin agonism. Two complementary appetite pathways activated at once.

Weight loss data

Phase 2 monotherapy cagrilintide at 2.4 mg/week: ~10% body weight reduction over 26 weeks. That’s roughly half of what tirzepatide delivers at its top dose, and similar to semaglutide 2.4 mg.

CagriSema in the REDEFINE program: ~15.6% at 20 weeks of combo therapy. Roughly 50% more loss than either component alone. The two pathways stack without crashing — that’s the whole pitch.

When cagrilintide alone is enough

• You’ve tried a GLP-1 and the GI side effects (nausea, constipation, the occasional vomiting episode) made it unsustainable. Amylin’s gastric-emptying slowdown is milder.
• You’re closer to maintenance than aggressive loss. A 10% trajectory is fine if you’re 20-30 lbs from goal and want a low-friction protocol.
• You’re concerned about long-term GLP-1 dependence and want something with shorter human-trial history but a different mechanism for cycling.

When CagriSema is the move

• You’re in the 50+ lbs overweight bracket where the extra 5-8 percentage points of weight loss meaningfully changes outcomes.
• You’ve already tolerated semaglutide and want to push further without going to tirzepatide.
• You want a single weekly injection instead of stacking two separate vials.

What we don’t know yet

Long-term (≥ 2 years) data on cagrilintide alone is thin. The FDA submission window is 2025-2026; until then it’s research-grade in most jurisdictions. Tolerability over multi-year use, weight regain after discontinuation, musculoskeletal effects — all open questions.

Practical notes

• Titrate up. Both compounds reward slow ramps. Starting cagrilintide at 0.3 mg/week and stepping every 4 weeks → 0.6 → 1.2 → 1.7 → 2.4 mg is the trial protocol and matches what compounding pharmacies recommend.
• Same day each week, independent of meals. Don’t try to “time” it with food the way some GLP-1 stackers do.
• If you discontinue, taper. Abrupt stop = rebound appetite within ~2 weeks.

The Peptora app has full protocols for both compounds with interaction warnings — if you stack cagrilintide with another GLP-1 outside CagriSema, the calculator will flag it.

Not medical advice — both compounds are research compounds in most jurisdictions and require a qualified healthcare provider to prescribe.